Chromosomal aberration and micronucleus studies of two topoisomerase (II) targeting anthracyclines

Journal of Environmental Biology

Volumn 30, Issue 3, 2009, Pages 409-412

  Khan, Fauzla ^a   Sherwani, Asma Farhat ^a   Afzal, Mohammad ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

CBMN assay; Chromosomal aberration assay; Doxorubicin; Idarubicin

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; IDARUBICIN;

ANTIBIOTICS; BIOASSAY; BIOLOGY; CHROMOSOME; NUCLEATION;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CHROMOSOME ABERRATION; CHROMOSOME BREAKAGE; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENOTOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE TRANSFORMATION TEST; MICRONUCLEUS TEST;

EID: 65649115821     PISSN: 02548704     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Albertini, R.J., D. Anderson, G.R. Dougla, L. Hagmar, K. Hemminki, F. Merlo, A.T. Natarajan, H. Norappa, D.E. Shuker, R. Tice, M.D. Waters, and A. Aitio: IPCS guidelines for the monitoring of genotoxic effects of carcinogens in humans. Mutat Res., 463, 111-172 (2000).
2. Bagchi, D., M. Bagchi, E.A. Hassoun, J. Kelly and S.J. Stohs: Adriamycin-induced hepatic and myocardial lipid peroxidation and DNA damage, and enhanced excretion of urinary lipid metabolites in rats. Toxicology, 95, 1-9 (1995).
3. Blasiak, J., E. Gloc, K. Wozniak, W. Mlynarski, M. Stolarska, T. Skorski and I. Majsterek: Genotoxicity of idarubicin and its modulation by vitamin C and E and amifostine. Chem. Biol. Interact., 140, 1-18 (2002).
4. Bridewell, D.J., G.J. Finlay and B.C. Baguley: Differential actions of aclarubicin and doxorubicin: The role of topoisomerase II. Oncol. Res., 9, 535-542 (1997).
5. Boffetta, P., O. Van Der Hel, H. Norppa, E. Fabianova, A. Fucic, S. Gundy, J Lazutka, A. Cebulska-Wasilewska, D. Puskailerova, A. Znaor, Z. Kelecsenyi, J. Kurtinaitis, J. Rachtan, A Forni, R Vermeulen and S. Bonassi: Chromosomal aberrations and cancer risk: Results of a cohort study from Central Europe. Am. J. Epidemiol., 165, 36-43 (2007).
6. Cersosimo, R.J.: Idarubicin: An anthracycline antineoplastic agent. Clin. Pharmacokinet., 11, 152-167 (1992).
7. Dunstan, H.M., C. Ludlow, S. Goehle, M. Cronk, P. Szankasi, D,R. Evans, J.A. Simon and J.R.J. Lamb: Cell-based assays for identification of novel double-strand break-inducing agents. J. Nat. Cancer Inst., 94, 88-94 (2002).
8. Eastmond, D.A. and J.D. Tucker: Identification of aneuploidy inducing agents using cytokinesis blocked human lymphocytes and an antikinetochore antibody. Environ, Mol. Mutagen., 13, 34-43 (1989).
9. EL Mahcly Sayed Othman, O.: Cytogenetic effect of the anticancer drug epirubicin on Chinese hamster cell line in vitro. Mulat Res., 468, 109-115 (2000).
10. El Zein, R.A., M.B. Schabath, C.J. Etzel, M.S. Lopez, J.D. Franklin and M.R. Spitz: Cytokinesis-blocked micronucleus assay as a novel biomarker for lung cancer risk. Cancer Res., 60, 6449-6456 (2006).
11. Fenech, M.: The in vitro micronucleus technique. Mulat. Res., 455, 81-95 (2000).
12. Fisher, R.A. and Y. Yates: Statistical Table for Biological, Agricultural and Medical Research. 6th Edn., Edinburg: Oliver and Boyd. p. 138 (1963).
13. Gentile, J.M., S. Rahimi, J. Zwiesler, G.J. Gentile and Ferguson, L.R.: Effects of selected antimutagens on the genotoxicity of antitumor agents. Mutat Res., 402, 289-298 (1998).
14. Gonzalez Cid, M., A.F. Fundia, M.T. Cuello and I. Larripa: Correlation between chromosome damage and apoptosis induced by fluclarabine and idarubicin in normal human lymphocytes. Toxicology, 171, 215-22 (2002).
15. Hagmar, L., A. Brogger, I.L. Hansteen, S. Heim, B, Hogsted, L. Knudesen, B. Lambert, K. Linnainmaa, F. Mitelman, I. Nordenson, C. Reuterwall, S. Salmooma, S. Skerfving and M. Sorsa: Cancer in humans predicted by increased level of chromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosomal damage. Cancer Res., 54, 2919-2922 (1994).
16. Hajji, N., S. Mateos, N. Paster, I. Dominguez and F. Cortes: Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor. Mutat. Res., 583, 26-35 (2005).
17. Hande, K.R.: Clinical applications of anticancer drugs targeted to lopoisomerase II. Biochem. Biophys. Acta, 1400, 173-84 (1998).
18. Henderson, I.C. and G.P. Canellos: Cancer of the breast: The past decade. N. Engl. J Med., 302, 78-90 (1980).
19. Hiddemann, W., M. Kneba, M. Dreyling, N. Schmitz, E. Lengfelder, R. Schmits, M. Reiser, B. Metzner, H. Harder, S. Hegewisch-Becker, T. Fischer, M. Kropff, H.E. Reis, M. Freund, B. Wormann, R. Fuchs, M. Flanker, J. Schimke, H. Eimermacher, L. Trumper, A. Aldaoud, R. Parwaresch and M. Unterhalt: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Gfade Lymphoma Study Group. Blood, 106, 3725-3732 (2005).
20. ISCN: An international system for human cytogenetic nomenclature for acquired chromosome aberrations. Birth Defects. The National Foundation, New York. p. 365 (1978).
21. Kantidze, O.L. and S.V. Razin: Chemotherapy related secondary leukemias: A role for DNA repair by error prone non-homologous end joining in topoisomerase II-induced chromosomal arrangements. Gene, 391, 76-79 (2007).
22. Kirsch Volders, M., T. Sofuni, M. Aardema, S. Albertinin, D. Eastmond, M. Fenech, M. Ishidate, E. Lorge, H. Norppa, J. Surrales, W. Von der Hude and A. Wakata: Report from the In Vitro Micronucleus Assay Working Group. Washington International Workshop on Genotoxicity Test Procedures, 25-26, March, 1999 (2000).
23. Mathur, N. and P. Bhatnagar: Mutagenecity assessment of textile dyes from Sanganer (Rajsthan). J Environ. Biol., 28, 123-126 (2007).
24. Migliore, L., R. Barale, D. Belluomini, A.G. Cognetti and N. Loprieno: Cytogenetic damage induced in human lymphocytes by adriamycin and vincristine: A comparison between micronucleus and chromosomal aberration assays. Toxicol. In Vitro, 1, 247-254 (1987).
25. Platel, D., P. Pouna, S. Bonoron Adele and J. Robert: Comparative cardotoxicity of Idarubicin and Doxorubicin using isolated perfused rat heart model. Anticancer Drugs, 10, 671-676 (1999).
26. Seiter, K.: Toxicity of the topoisomerase II inhibitors. Expert Opin. Drug Saf., 4, 219-34 (2005).
27. Siddique, Y.H. and M. Afzal: Evaluation of genotoxic potential of norethynodrel in human lymphocytes in vitro. J. Environ. Biol., 26, 387-392 (2005).
28. Stopper, H., G. Boos, M. Clark and F. Gieseler: Are topoisomerase II inhibitor-induced micronuclei in vitro a predictive marker for the compounds ability to cause secondary leukemias after treatment? Toxicol. Lett., 104, 103-110 (1999).
29. Suzuki, H. and S. Nakane: Differential induction of chromosomal aberrations by topoisomerase inhibitors in cultured Chinese hamster cells. Biol. Pharm. Bull., 17, 222-226 (1994).
30. Szulawska, A. and M. Czyz: Molecular mechanism of anthracycline action. Postepy Hig. Med. Dosw., 60, 78-100 (2006).
31. Watt, J.L. and G.S. Stephen: Lymphocyte culture for chromosome analysis. In: Human cytogenetics, a practicala approach (Eds.: D.E. Rooney and B.H. Czepulkowski). Oxford, UK, IRL Press. pp. 39-56 (1986).
32. Zhang, H.M. and N.Q. Li: Electrochemical studies of the interaction of adriamycin to DNA. J. Pharm. Biomed. Anal., 22, 67-73 (2000).